QuickLinks -- Click here to rapidly navigate through this document

PROSPECTUS SUPPLEMENT

        To Prospectus dated June 5, 2001

Filed Pursuant to Rule 424 (b) (3) of the Rules and Regulations
Under the Securities Act of 1933
Registration Statement No. 333-92383

Charles River Laboratories International, Inc.

[Name of Issuer]

Charles River Laboratories International, Inc.
Common Stock
Warrants To Purchase Common Stock

[Title of Security]

RECENT DEVELOPMENTS

We have attached to the prospectus supplement, and incorporated by reference into it, the Form 10-Q Quarterly Report of Charles River Laboratories International, Inc. for the Quarter Ending June 29, 2002 filed with the Securities and Exchange Commission on August 12, 2002.

---

August 14, 2002

---

---

---

UNITED STATES
SECURITES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

---

FORM 10-Q

ý	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED JUNE 29, 2002 OR

o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number 333-92383

---

CHARLES RIVER LABORATORIES
INTERNATIONAL, INC.
(Exact Name of Registrant as specified in its Charter)

251 BALLARDVALE STREET, WILMINGTON, MASSACHUSETTS 01887
(Address of Principal Executive Offices) (Zip Code)

978-658-6000
(Registrant's Telephone Number, Including Area Code)

---

        Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý    No o

        As of July 19, 2002 there were 44,744,023 shares of the registrant's common stock outstanding

---

---

---

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
FORM 10-Q
For the Quarterly Period Ended June 29, 2002
Table of Contents

					Page
Part I.    Financial Information
	Item 1.		Financial Statements
			Condensed Consolidated Statements of Income (Unaudited) for the three months ended June 29, 2002 and June 30, 2001		3
			Condensed Consolidated Statements of Income (Unaudited) for the six months ended June 29, 2002 and June 30, 2001		4
			Condensed Consolidated Balance Sheets as of June 29, 2002 (Unaudited) and December 29, 2001		5
			Condensed Consolidated Statements of Cash Flows (Unaudited) for the six months ended June 29, 2002 and June 30, 2001		6
			Notes to Unaudited Condensed Consolidated Interim Financial Statements		7
	Item 2.		Management's Discussion and Analysis of Financial Condition and Results of Operations		17
	Item 3.		Quantitative and Qualitative Disclosures about Market Risk		22
Part II.    Other Information
	Item 4.		Submission of Matters to a Vote of Security Holders		24
	Item 6.		Exhibits and Reports on Form 8-K		25

2

---

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)

(dollars in thousands except for per share data)

			Three Months Ended
			June 29, 2002			June 30, 2001
Net sales related to products			$	72,470		$	60,644
Net sales related to services				64,031			56,176
Total net sales				136,501			116,820
Costs and expenses
	Cost of products sold			40,206			33,788
	Cost of services provided			43,895			39,262
	Selling, general and administrative			21,387			17,285
	Amortization of goodwill and intangibles			631			1,993
Operating income				30,382			24,492
Other income (expense)
	Interest income			697			346
	Interest expense			(2,958	)		(5,940	)
	Other income (expense)			1,160			(122	)
Income before income taxes, minority interests, earnings from equity investments and extraordinary item				29,281			18,776
Provision for income taxes				11,419			7,659
Income before minority interests, earnings from equity investments and extraordinary item				17,862			11,117
Minority interests				(619	)		(652	)
Earnings from equity investments				177			136
Income before extraordinary item				17,420			10,601
Extraordinary loss, net of tax benefit of $698 and $852, respectively				(1,092	)		(1,583	)
Net income			$	16,328		$	9,018
Earnings per common share before extraordinary item
	Basic		$	0.39		$	0.26
	Diluted		$	0.36		$	0.24
Earnings per common share after extraordinary item
	Basic		$	0.37		$	0.22
	Diluted		$	0.34		$	0.21

See Notes to Condensed Consolidated Financial Statements

3

---

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)

(dollars in thousands except for per share data)

			Six Months Ended
			June 29, 2002			June 30, 2001
Net sales related to products			$	143,028		$	122,722
Net sales related to services				127,293			93,129
Total net sales				270,321			215,851
Costs and expenses
	Cost of products sold			79,151			70,206
	Cost of services provided			88,811			65,213
	Selling, general and administrative			42,306			32,745
	Amortization of goodwill and intangibles			1,261			3,821
Operating income				58,792			43,866
Other income (expense)
	Interest income			1,210			599
	Interest expense			(6,863	)		(12,898	)
	Other income (expense)			1,077			433
Income before income taxes, minority interests, earnings from equity investments and extraordinary item				54,216			32,000
Provision for income taxes				21,144			13,214
Income before minority interests, earnings from equity investments and extraordinary item				33,072			18,786
Minority interests				(1,381	)		(1,216	)
Earnings from equity investments				259			219
Income before extraordinary item				31,950			17,789
Extraordinary loss, net of tax benefit of $11,415 and $980, respectively				(17,854	)		(1,820	)
Net income			$	14,096		$	15,969
Earnings per common share before extraordinary item
	Basic		$	0.72		$	0.46
	Diluted		$	0.67		$	0.42
Earnings per common share after extraordinary item
	Basic		$	0.32		$	0.42
	Diluted		$	0.31		$	0.38

See Notes to Condensed Consolidated Financial Statements

4

---

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(dollars in thousands)

				June 29, 2002			December 29, 2001
				(Unaudited)
Assets
Current assets
	Cash and cash equivalents			$	84,712		$	58,271
	Trade receivables, less allowances of $2,445 and $2,119, respectively				99,829			98,478
	Inventories				39,454			39,056
	Prepaid expenses and other current assets				15,713			14,349
		Total current assets			239,708			210,154
	Property, plant and equipment, net				169,088			155,919
	Goodwill, net				87,416			52,087
	Other intangibles, net				19,691			38,287
	Investments in affiliates				3,187			3,002
	Deferred tax asset				86,033			87,781
	Other assets				24,757			24,132
		Total assets		$	629,880		$	571,362
Liabilities and Shareholders' Equity
Current liabilities
	Accounts payable			$	12,240		$	13,868
	Accrued compensation				21,874			25,736
	Deferred income				22,168			22,210
	Accrued liabilities				33,701			28,899
	Accrued income taxes				7,304			4,048
	Other current liabilities				5,089			3,771
		Total current liabilities			102,376			98,532
Long-term debt					188,705			155,506
Capital lease obligations					343			361
Accrued ESLIRP					11,801			11,383
Other long-term liabilities					3,733			3,082
		Total liabilities			306,958			268,864
Commitments and contingencies (Note 8)
Minority interests					13,386			12,988
Shareholders' equity
	Preferred stock, $0.01 par value; 20,000,000 shares authorized; no shares issued and outstanding				—			—
	Common stock, $0.01 par value; 120,000,000 shares authorized; 44,742,208 and 44,189,650 shares issued and outstanding at June 29, 2002 and December 29, 2001, respectively				447			442
	Capital in excess of par value				592,608			588,909
	Retained earnings				(269,072	)		(283,168	)
	Loans to officers				(149	)		(341	)
	Unearned compensation				(255	)		(316	)
	Accumulated other comprehensive income				(14,043	)		(16,016	)
		Total shareholders' equity			309,536			289,510
		Total liabilities and shareholders' equity		$	629,880		$	571,362

See Notes to Condensed Consolidated Financial Statements

5

---

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

(dollars in thousands)

				Six Months Ended
				June 29, 2002			June 30, 2001
Cash flows relating to operating activities
Net income				$	14,096		$	15,969
Adjustments to reconcile net income to net cash provided by operating activities:
	Depreciation and amortization				11,050			12,029
	Amortization of debt issuance costs and discounts				937			808
	Provision for doubtful accounts				293			—
	Extraordinary loss, net of tax				17,854			1,820
	Earnings from equity investments				(259	)		(220	)
	Minority interests				1,381			1,216
	Deferred income taxes				9,233			9,009
	Windfall tax benefit from exercises of employee stock options				1,166			897
	Loss on disposal of property, plant, and equipment				1,574			306
	Other non-cash items				65			23
Changes in assets and liabilities:
	Trade receivables				953			(14,877	)
	Inventories				693			(2,443	)
	Prepaids and other current assets				(857	)		(2,475	)
	Other assets				391			(746	)
	Accounts payable				(2,789	)		(3,756	)
	Accrued compensation				(4,509	)		2,698
	Deferred income				289			3,985
	Accrued and other liabilities				(1,140	)		(7,472	)
	Accrued income taxes				2,810			1,842
	Accrued ESLIRP				418			525
	Other long-term liabilities				(59	)		(756	)
		Net cash provided by operating activities			53,590			18,382
Cash flows relating to investing activities
	Capital expenditures				(14,306	)		(11,726	)
	Contingent payments for prior year acquisitions				—			(250	)
	Acquisition of businesses, net of cash acquired				(19,527	)		(51,265	)
		Net cash used in investing activities			(33,833	)		(63,241	)
Cash flows relating to financing activities
	Proceeds from long term debt and revolving credit facility				187,273			43,534
	Payments on long-term debt and revolving credit facility				(154,104	)		(59,898	)
	Payments of deferred financing cost				(6,123	)		(984	)
	Payments on capital lease obligations				(55	)		(4,145	)
	Proceeds from issuance of common stock, net of transaction fees				—			62,222
	Proceeds from exercises of employee stock options				792			633
	Proceeds from exercises of warrants				1,742			—
	Premium paid on early retirement of debt				(23,886	)		(210	)
	Dividends paid to minority interests				(1,470	)		(729	)
	Payments received from officers				192			579
		Net cash provided by financing activities			4,361			41,002
Effect of exchange rate changes on cash and cash equivalent					2,323			(856	)
Net change in cash and cash equivalents					26,441			(4,713	)
Cash and cash equivalents, beginning of period					58,271			33,129
Cash and cash equivalents, end of period				$	84,712		$	28,416
Supplemental cash flow information
	Cash paid for interest			$	5,894		$	11,795
	Cash paid for taxes				6,389			2,877

See Notes to Condensed Consolidated Financial Statements

6

---

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(dollars in thousands)

1. Basis of Presentation

        The condensed consolidated interim financial statements are unaudited, and certain information and footnote disclosures related thereto normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted in accordance with Rule 10-01 of Regulation S-X. In the opinion of management, the accompanying unaudited condensed consolidated financial statements were prepared following the same policies and procedures used in the preparation of the audited financial statements and reflect all adjustments (consisting of normal recurring adjustments) considered necessary to fairly state the financial position and results of operations of Charles River Laboratories International, Inc. ("the Company"). The results of operations for the interim periods are not necessarily indicative of the results for the entire fiscal year. These condensed consolidated financial statements should be read in conjunction with the Company's Annual Report on Form 10-K for the year ended December 29, 2001.

        Certain amounts in the prior year financial statements and related notes have been reclassified to conform with current year presentation.

2. Long Term Debt

        On May 29, 2002, the Company repaid all of the outstanding senior secured term loan facilities, including $14,000 term loan A facility, $41,100 term loan B facility and $13,500 term loan C facility. The Company recorded an extraordinary loss before tax of $1,790 due to the write-off of deferred financing costs. The extraordinary loss was recorded in the condensed consolidated statement of income net of a tax benefit of $698.

        On February 14, 2002, the Company completed a tender offer for $79,728 par value for all of the 13.5% senior subordinated notes. The Company recorded an extraordinary loss before tax of $27,479, due to the payment of premiums related to the early extinguishment of debt ($23,886), the write-off of deferred financing costs ($2,726) and issuance discounts ($867). The extraordinary loss was recorded in the condensed consolidated statement of income net of a tax benefit of $10,717.

        On January 24, 2002, the Company issued $175,000 par value of senior convertible debentures through a private placement offering. On February 11, 2002, the Company issued an additional $10,000 par value of senior convertible debentures through the additional purchase option. The Company received approximately $179,450, net of underwriter discounts. The senior convertible debentures will accrue interest at an initial annual rate of 3.5%, payable semi-annually in arrears, beginning August 1, 2002. The senior convertible debentures will mature in 2022 and are convertible into shares of the Company's common stock at a conversion price of $38.87, subject to adjustment under certain circumstances. On or after February 5, 2005, the Company may redeem for cash all or part of the debentures that have not been previously converted at the redemption prices set forth in the purchase agreement. Holders may require the Company to repurchase for cash all or part of their debentures on February 1, 2008, February 1, 2013 or February 1, 2017 at a price equal to 100% of the par value of the debentures plus accrued interest up to but not including the date of repurchase. In addition, upon a change in control of the Company occurring on or prior to February 1, 2022, each holder may require the Company to repurchase all or a portion of such holder's debentures for cash. The Company used a portion of the net proceeds from the senior convertible debenture offering to retire all of the 13.5% senior subordinated notes through a tender offer.

7

---

3. Business Acquisitions

        On June 7, 2002, Charles River Europe GmbH, a wholly owned subsidiary of Charles River Laboratories Inc., the Company's wholly owned subsidiary, acquired 100% of the voting equity interests of privately held Biological Laboratories Europe Limited ("BioLabs"). Consideration, including acquisition expenses, was $22,900, net of cash acquired of $2,998. The consideration consists of $18,526 in cash and $4,374 in future payments, of which $2,360 is to be paid in the third quarter of 2002, $1,888 is to be paid to two selling shareholders of BioLabs over a three year period and $126 in acquisition costs. BioLabs, located in Western Ireland, provides a broad range of services supporting the discovery, development and manufacturing of pharmaceutical, medical devices and animal and human health products. BioLabs was acquired to strengthen the Company's existing biomedical products and services segment by adding new capabilities to service the large and growing global animal health and medical device industry. The acquisition was recorded as a purchase business combination in accordance with Statement of Financial Accounting Standards No. 141, "Business Combinations". The Company consolidated the operations of BioLabs from the date of acquisition.

        As of June 29, 2002, the purchase price allocation for BioLabs had not been completed, however, it is expected to be finalized by the end of fiscal year 2002. The estimated allocation of purchase price as of June 29, 2002 is as follows:

        On January 8, 2001, Charles River Laboratories, Inc. ("CRL"), the Company's wholly owned subsidiary, purchased 100% of the common stock of Pathology Associates International Corporation ("PAI"). Consideration, including acquisition expenses, of $35,238 was paid with respect to this acquisition, consisting of $25,557 of cash and a $12,000 callable convertible note. This acquisition was recorded as a purchase business combination and CRL consolidated the operations of PAI from the date of acquisition.

        Effective February 27, 2001, CRL acquired Primedica Corporation ("Primedica") for consideration, including acquisition expenses, of $51,107. Consideration was comprised of $25,708 of cash, $16,375 of the Company's common stock and $9,024 in assumed debt. This acquisition was recorded as a purchase business combination and CRL consolidated the operations of Primedica from the date of acquisition.

        On July 20, 2001, CRL purchased 100% of the common stock of Genetic Models, Inc. ("GMI") for cash consideration of $4,000. This acquisition was recorded as a purchase business combination in accordance with Statement of Financial Accounting Standards No. 141, "Business Combinations". The Company consolidated the operations of GMI from the date of acquisition.

8

---

        The following selected unaudited pro forma consolidated results of operations are presented as if each of the acquisitions had occurred as of the beginning of the period immediately preceding the period of acquisition after giving effect to certain adjustments for the amortization of goodwill for the three and six months ended June 30, 2002, additional interest expense and related income tax effects. The pro forma data is for informational purposes only and does not necessarily reflect the results of operations had the companies operated as one during the period. No effect has been given for synergies, if any, that may have been realized through the acquisitions.

			Three Months Ended						Six Months Ended
			June 29, 2002			June 30, 2001			June 29, 2002			June 30, 2001
Net sales			$	138,269		$	119,924		$	274,348		$	233,888
Income before extraordinary item				17,693			10,911			32,494			18,328
Net income				16,601			9,328			14,640			16,508
Earnings per common share before extraordinary item
	Basic		$	0.40		$	0.27		$	0.73		$	0.48
	Diluted		$	0.37		$	0.25		$	0.68		$	0.44
Earnings per common share after extraordinary item
	Basic		$	0.37		$	0.23		$	0.33		$	0.43
	Diluted		$	0.34		$	0.21		$	0.33		$	0.39

        Refer to Note 5 for further discussion of the method of computation of earnings per share.

4. Restructuring Charges

        During the fourth quarter of 2001, the Company recorded a restructuring charge associated with the closing of a San Diego, California facility. Approximately 40 employees were terminated as a result of this action.

        During the fourth quarter of 2000, the Company recorded a restructuring charge associated with the closing of a facility in France. During 2001, the Company recorded additional charges relating to the settlement of labor disputes which originated during the first quarter of 2001. Approximately 60 employees were terminated as a result of the restructuring.

        A summary of the activities associated with the above restructuring charges and the related liabilities balance as of December 29, 2001 and June 29, 2002 are as follows:

        The Company has closed both the San Diego facility and the French facility and expects the reserves to be fully utilized by the end of fiscal year 2002.

9

---

5. Earnings per Share

        Basic earnings per share for the three and six month periods ended June 29, 2002 and June 30, 2001 were computed by dividing earnings available to common shareholders for these periods by the weighted average number of common shares outstanding in the respective periods.

        The weighted average number of common shares outstanding in the three and six month periods ended June 29, 2002 and June 30, 2001 have been adjusted to include common stock equivalents for the purpose of calculating diluted earnings per share before and after the extraordinary item for these periods.

        The following table illustrates the reconciliation of the numerator and denominator of the basic and diluted earnings per share before and after the extraordinary item computations:

			Three Month Period Ended						Six Month Period Ended
			June 29, 2002			June 30, 2001			June 29, 2002			June 30, 2001
Numerator:
Income before extraordinary item			$	17,420		$	10,601		$	31,950		$	17,789
Extraordinary loss, net of tax benefit				(1,092	)		(1,583	)		(17,854	)		(1,820	)
Income after extraordinary item for purposes of calculating basic earnings per share				16,328			9,018			14,096			15,969
After tax equivalent of interest expense:
	3.5% senior convertible debentures			996			—			1,707			—
	2% convertible note			—			27			8			55
Income for purposes of calculating diluted earnings per share			$	17,324		$	9,045		$	15,811		$	16,024
Denominator:
Weighted average shares outstanding—Basic				44,557,027			40,175,630			44,405,961			38,403,244
Effect of dilutive securities:
	3.5% senior convertible debentures			4,759,455			—			4,080,239			—
	Stock options			1,076,211			1,036,294			1,035,226			1,007,059
	Warrants			659,682			2,711,927			758,691			2,693,036
	2% convertible note			—			128,315			17,626			128,315
Weighted average shares outstanding—Diluted				51,052,375			44,052,166			50,297,743			42,231,654
Basic earnings per share before extraordinary item			$	0.39		$	0.26		$	0.72		$	0.46
Basic loss per share on extraordinary item				(0.02	)		(0.04	)		(0.40	)		(0.04	)
Basic earnings per share after extraordinary item			$	0.37		$	0.22		$	0.32		$	0.42
Diluted earnings per share before extraordinary item			$	0.36		$	0.24		$	0.67		$	0.42
Diluted loss per share on extraordinary item				(0.02	)		(0.03	)		(0.36	)		(0.04	)
Diluted earnings per share after extraordinary item			$	0.34		$	0.21		$	0.31		$	0.38

10

---

6. Supplemental Balance Sheet Information

        The composition of inventories is as follows:

        Inventories are stated at the lower of cost or market. Cost is determined principally on the average cost method.

        The composition of property, plant and equipment is as follows:

7. Comprehensive Income

        The components of comprehensive income for the three and six month periods ended June 29, 2002 and June 30, 2001 are set forth below:

		Three Month Period Ended						Six Month Period Ended
		June 29, 2002			June 30, 2001			June 29, 2002			June 30, 2001
Net income		$	16,328		$	9,018		$	14,096		$	15,969
Foreign currency translation adjustment, net of tax			2,672			(1,057	)		1,973			(3,752	)
Comprehensive income		$	19,000		$	7,961		$	16,069		$	12,217

11

---

8. Commitments and Contingencies

        Various lawsuits, claims and proceedings of a nature considered normal to its business are pending against the Company. In the opinion of management, the outcome of such proceedings and litigations currently pending will not materially affect the Company's consolidated financial statements.

        On April 27, 2001, the Company's French subsidiaries obtained a favorable legal judgement in a contract dispute, with a damages award of approximately $3,500. As of June 29, 2002, the Company has received the full damage award of approximately $3,500 under the legal judgment. The Company received $2,240 during fiscal year 2001 and the remaining $1,260 during the second quarter of 2002. As the defendant has appealed the decision, the proceeds are included as deferred income in the consolidated balance sheet as of June 29, 2002 and December 29, 2001.

        The Company has provided letters of credit in favor of the insurance carriers in the amount of $3,063.

9. Business Segment Information

        The following table presents sales and other financial information by product line segment for the three and six month periods ended June 29, 2002 and June 30, 2001. Sales to unaffiliated customers represent net sales originating in entities primarily engaged in either research models or biomedical products and services.

			Three Month Period Ended						Six Month Period Ended
			June 29, 2002			June 30, 2001			June 29, 2002			June 30, 2001
Research Models
	Net sales		$	56,544		$	48,013		$	113,443		$	97,487
	Gross margin			26,096			20,917			52,159			41,465
	Operating income			18,993			13,681			38,525			26,952
	Depreciation and amortization			2,326			2,331			4,541			4,736
	Capital expenditures			5,083			2,479			6,539			4,392
Biomedical Products and Services
	Net sales		$	79,957		$	68,807		$	156,878		$	118,364
	Gross margin			26,304			22,853			50,200			38,967
	Operating income			16,317			12,476			30,438			20,956
	Depreciation and amortization			3,290			4,259			6,509			7,293
	Capital expenditures			4,688			4,994			7,767			7,334

12

---

        A reconciliation of segment operating income to consolidated operating income is as follows:

		Three Month Period Ended						Six Month Period Ended
		June 29, 2002			June 30, 2001			June 29, 2002			June 30, 2001
Total segment operating income		$	35,310		$	26,157		$	68,963		$	47,908
Unallocated corporate overhead			(4,928	)		(1,665	)		(10,171	)		(4,042	)
Consolidated operating income		$	30,382		$	24,492		$	58,792		$	43,866

10. Goodwill and Other Intangible Assets

        Effective at the beginning of fiscal year 2002, the Company adopted Statement of Financial Accounting Standards No. 142, "Goodwill and Other Intangible Assets" (FAS 142), which establishes financial accounting and reporting standards for acquired goodwill and other intangible assets. Under FAS 142, goodwill and indefinite lived intangible assets are no longer amortized but are reviewed at least annually for impairment. Separate intangible assets that have finite useful lives will continue to be amortized over their useful lives.

        FAS 142 requires that goodwill be tested annually for impairment using a two-step process. The first step is to identify a potential impairment and, in transition, this step must be measured as of the beginning of the year of adoption. The Company completed the first step during the second quarter of 2002, which resulted in identifying no potential goodwill impairments as of the beginning of fiscal year 2002. The second step of the goodwill impairment test, which measures the amount of the impairment loss (measured as of the beginning of the year of adoption), is not applicable for fiscal year 2002. Intangible assets deemed to have an indefinite life will be tested for impairment using a one-step process which compares the fair value to the carrying amount of the asset as of the beginning of the fiscal year. Pursuant to the requirements of FAS 142, this impairment test was completed during the first quarter of 2002. The Company has determined that its identifiable intangible assets with indefinite useful lives were not impaired.

13

---

        The following table displays goodwill and other intangible assets not subject to amortization and other intangible assets that continue to be subject to amortization:

				June 29, 2002						December 29, 2001
				Gross Carrying Amount			Accumulated Amortization			Gross Carrying Amount			Accumulated Amortization
Goodwill				$	99,795		$	(12,379	)	$	60,866		$	(8,779	)
Other intangible assets not subject to amortization				$	3,438		$	—		$	3,438		$	—
Other intangible assets subject to amortization:
	Assembled workforce				—			—			20,925			(3,542	)
	Customer relationships				11,491			(2,107	)		11,491			(1,724	)
	Customer contracts				3,455			(1,586	)		3,455			(1,111	)
	Trademarks and trade names				3,000			(405	)		3,000			(253	)
	Standard operating procedures				1,208			(254	)		1,208			(156	)
	Other identifiable intangible assets				3,299			(1,848	)		3,237			(1,681	)
Total other intangible assets				$	25,891		$	(6,200	)	$	46,754		$	(8,467	)
		Total goodwill and other intangible assets		$	125,686		$	(18,579	)	$	107,620		$	(17,246	)

        The changes in the gross carrying amount and accumulated amortization of goodwill from December 29, 2001 to June 29, 2002 are as follows:

			Research Models						Biomedical Products and Services						Total
			Gross Carrying Amount			Accumulated Amortization			Gross Carrying Amount			Accumulated Amortization			Gross Carrying Amount			Accumulated Amortization
Balance at December 29, 2001			$	8,101		$	(1,108	)	$	52,765		$	(7,671	)	$	60,866		$	(8,779	)
Adjustments to goodwill:
	Assembled workforce reclassification			—			—			20,925			(3,542	)		20,925			(3,542	)
	Acquisitions			—			—			17,841			—			17,841			—
	Foreign currency translation			—			—			163			(58	)		163			(58	)
Balance at June 29, 2002			$	8,101		$	(1,108	)	$	91,694		$	(11,271	)	$	99,795		$	(12,379	)

        Estimated amortization expense for each of the next five years is as follows:

14

---

        The following selected pro forma consolidated results are presented as if Statement of Financial Accounting Standards No. 141, "Business Combinations" and FAS 142 had been adopted at the beginning of fiscal year 2001 and accordingly amortization for goodwill and other identifiable intangible assets has been eliminated.

		Three Month Period Ended June 30, 2001			Six Month Period Ended June 30, 2001
Reported income before extraordinary item		$	10,601		$	17,789
Amortization of goodwill, net of tax			897			1,626
Pro forma income before extraordinary item			11,498			19,415
Extraordinary item, net of tax			(1,583	)		(1,820	)
Pro forma net income		$	9,915		$	17,595
Reported basic earning per share before extraordinary item		$	0.26		$	0.46
Basic earnings per share on amortization of goodwill, net of tax			0.02			0.04
Pro forma basic earnings per share before extraordinary item			0.28			0.50
Basic loss per share on extraordinary item, net of tax			(0.04	)		(0.04	)
Pro forma basic earnings per share after extraordinary item		$	0.24		$	0.46
Reported diluted earnings per share before extraordinary item		$	0.24		$	0.42
Dilutive earnings per share on amortization of goodwill, net of tax			0.02			0.04
Pro forma diluted earnings per share before extraordinary item			0.26			0.46
Dilutive loss per share on extraordinary item, net of tax			(0.03	)		(0.04	)
Pro forma diluted earnings per share after extraordinary item		$	0.23		$	0.42

11. Recently Issued Accounting Standards

        In April 2002, the Financial Accounting Standards Board (FASB) issued Statement of Financial Accounting Standards No. 145, "Rescission of FASB Statements No. 4, 44, and 64, Amendment of FASB Statement No. 13, and Technical Corrections" (FAS 145). FAS 145 eliminates the requirement that gains and losses from the extinguishment of debt be aggregated and, if material, classified as an extraordinary item, net of the related income tax effect. However, an entity would not be prohibited from classifying such gains and losses as extraordinary items so long as they are both unusual in nature and infrequent in occurrence. This provision of FAS 145 will be effective for the Company as of the beginning of fiscal year 2003. The Company expects to reclassify losses on extinguishment of debt that have been classified as an extraordinary item in prior periods presented.

        In July 2002, the FASB issued Statement of Financial Accounting Standards No. 146, "Accounting for Costs Associated with Exit or Disposal Activities" (FAS 146), which nullifies Emerging Issues Task Force (EITF) Issue No. 94-3, "Liability Recognition for Certain Employee Termination Benefits and

15

---

Other Costs to Exit an Activity (including Certain Costs Incurred in a Restructuring)". FAS 146 requires a liability for a cost associated with an exit or disposal activity be recognized and measured initially at its fair value in the period in which the liability is incurred. If fair value cannot be reasonably estimated, the liability shall be recognized initially in the period in which fair value can be reasonably estimated. In periods subsequent to the initial measurement, changes to the liability resulting from a revision to either the timing or the amount of estimated cash flows shall be recognized as an adjustment to the liability in the period of the change. The provisions of FAS 146 will be effective for the Company prospectively for exit or disposal activities initiated after December 29, 2002. The Company is in the process of assessing the impact of FAS 146 on its consolidated financial statements.

16

---

Item 2.    Management's Discussion and Analysis of Financial Condition and Results of Operations

Six Months Ended June 29, 2002 Compared to the Six Months Ended June 30, 2001

        Net Sales.    Net sales for the six months ended June 29, 2002 were $270.3 million, an increase of $54.4 million, or 25.2%, from $215.9 million for the six months ended June 30, 2001. On a pro forma basis, sales increased 17.3% for the six months ended June 29, 2002. Pro forma sales includes net sales of the companies we acquired in 2002 and 2001 as if they occurred at the beginning of fiscal 2001.

        Research Models.    Net sales of research models for the six months ended June 29, 2002 were $113.4 million, an increase of $15.9 million, or 16.3%, from $97.5 million for the six months ended June 30, 2001. Small animal research model sales increased in North America by 18.0% due to an increase in unit volume, a shift to higher priced specialty units including the models from our 2001 acquisition of Genetic Models, Inc. ("GMI") and improved pricing. Small animal research model sales in Europe increased 12.5%, driven in part by an increase in unit volume, a shift to higher priced specialty units and increased equipment sales. Small animal research model sales in Japan increased 15.1% for the six months ended June 29, 2002, excluding the negative impact from currency translation of $1.9 million, due to competitor product quality issues through the second quarter of 2002. Sales from our large animal breeding and import conditioning business increased by $3.8 million due mainly to the timing of animal shipments for the six months ended June 29, 2002.

        Biomedical Products and Services.    Net sales of biomedical products and services for the six months ended June 29, 2002 were $156.9 million, an increase of $38.5 million, or 32.5%, compared to $118.4 million for the six months ended June 30, 2001. Pro forma sales of biomedical products and services increased 19.5% for the six months ended June 29, 2002 compared to the six months ended June 30, 2001. The increase in net sales of biomedical products and services is due to the continued growth in outsourcing in the pharmaceutical industry and our acquisitions. Biological Laboratories Europe Limited ("BioLabs"), which we acquired on June 7, 2002, along with our 2001 acquisition, Primedica Corporation ("Primedica"), contributed $46.4 million of sales for the six months ended June 29, 2002, compared to $31.2 million from Primedica for the six months ended June 30, 2001.

        Cost of Products Sold and Services Provided.    Cost of products sold and services provided for the six months ended June 29, 2002 was $168.0 million, an increase of $32.6 million, or 24.1%, from $135.4 million for the six months ended June 30, 2001. Cost of products sold and services provided for the six months ended June 29, 2002 was 62.2% of the net sales compared to 62.7% for the six months ended June 30, 2001.

        Research Models.    Cost of products sold and services provided for research models for the six months ended June 29, 2002 was $61.3 million, an increase of $5.3 million, or 9.5%, compared to $56.0 million for six months ended June 30, 2001. Cost of products sold and services provided for the six months ended June 29, 2002 improved to 54.1% of net sales compared to 57.4% of net sales for the six months ended June 30, 2001. Cost of products sold and services provided increased at a lower rate than net sales due to reduced production costs resulting from the closure of a French facility and increased sales which resulted in improved capacity utilization and better efficiencies.

        Biomedical Products and Services.    Cost of products sold and services provided for biomedical products and services for the six months ended June 29, 2002 was $106.7 million, an increase of $27.3 million, or 34.4%, compared to $79.4 million for the six months ended June 30, 2001. Cost of products sold and services provided as a percentage of net sales increased to 68.0% for the six months ended June 29, 2002 from 67.1% for the six months ended June 30, 2001. Cost of products sold and services provided increased as a percentage of net sales for the six months ended June 29, 2002 primarily due to the addition of Primedica which operated at lower gross margins than the remainder of our biomedical products and services businesses.

17

---

        Selling, General and Administrative Expenses.    Selling, general and administrative expenses for the six months ended June 29, 2002 were $42.3 million, an increase of $9.6 million, or 29.4%, from $32.7 million for the six months ended June 30, 2001. Selling, general and administrative expenses for the six months ended June 29, 2002 was 15.6% of net sales compared to 15.1% of net sales for the six months ended June 30, 2001.

        Research Models.    Selling, general and administrative expenses for research models for the six months ended June 29, 2002 were $13.6 million, a decrease of $0.6 million compared to $14.2 million for the six months ended June 30, 2001. Selling, general and administrative expenses for the six months ended June 29, 2002 were 12.0% of net sales, compared to 14.6% for the six months ended June 30, 2001, principally due to economies of scale and a charge of $1.0 million associated with the closing of a French facility during the six months ended June 30, 2001.

        Biomedical Products and Services.    Selling, general and administrative expenses for biomedical products and services for the six months ended June 29, 2002 were $18.5 million, an increase of $4.0 million, or 27.6%, compared to $14.5 million for the six months ended June 30, 2001. Selling, general and administrative expenses for the six months ended June 29, 2002 was 11.8% of net sales compared to 12.2% of net sales for the six months ended June 30, 2001. Selling, general and administrative expenses increased at a lower rate than net sales due to cost containment during the six months ended June 29, 2002.

        Unallocated Corporate Overhead.    Unallocated corporate overhead, which consists of various corporate expenses, was $10.2 million for the six months ended June 29, 2002, compared to $4.0 million for the six months ended June 30, 2001. The change was caused by decreased pension income and increased administrative expenses including investor relations, security and corporate insurance costs.

        Amortization of Goodwill and Other Intangibles.    Amortization of goodwill and other intangibles for the six months ended June 29, 2002 was $1.3 million, a decrease of $2.5 million from $3.8 million for the six months ended June 30, 2001. The decrease was due to our adoption of the Financial Accounting Standards Board (FASB) Statement of Financial Accounting Standards No. 142, "Goodwill and Other Intangible Assets" (FAS 142). During the second quarter of 2002, we completed the goodwill impairment test, which identified no potential goodwill impairment as of the beginning of the fiscal year 2002.

        Operating Income.    Operating income for the six months ended June 29, 2002 was $58.8 million, an increase of $14.9 million, or 33.9%, from $43.9 million for the six months ended June 30, 2001. Operating income for the six months ended June 29, 2002 was 21.8% of net sales, compared to 20.3% of net sales for the six months ended June 30, 2001.

        Research Models.    Operating income from sales of research models for the six months ended June 29, 2002 was $38.5 million, an increase of $11.5 million, or 42.6%, from $27.0 million for the six months ended June 30, 2001. Operating income from sales of research models for the six months ended June 29, 2002 was 34.0% of net sales, compared to 27.7% for the six months ended June 30, 2001 due to increased sales and higher gross margins primarily from improved capacity utilization.

        Biomedical Products and Services.    Operating income from sales of biomedical products and services for the six months ended June 29, 2002 was $30.4 million, an increase of $9.4 million, or 44.8%, from $21.0 million for the six months ended June 30, 2001. Operating income from sales of biomedical products and services for the six months ended June 29, 2002 increased to 19.4% of net sales, compared to 17.7% of net sales for the six months ended June 30, 2001, due to the benefit associated with the elimination of goodwill amortization, along with higher operating cost efficiency, partially offset by the lower margins from the acquisition of Primedica.

18

---

        Interest Expense.    Interest expense for the six months ended June 29, 2002 was $6.9 million, compared to $12.9 million for the six months ended June 30, 2001. The $6.0 million decrease is primarily due to the impact of the tender offer for all of the 13.5% senior subordinated notes completed during the first quarter of 2002, lower interest rate on our 3.5% senior convertible debenture issuance and the payoff of all of the term loans during the second quarter of 2002.

        Other Income.    Other income for the six months ended June 29, 2002 was $1.1 million, compared to $0.4 million for the six months ended June 30, 2001. The increase is primarily due to net foreign currency gains.

        Income Taxes.    The effective tax rate for the six months ended June 29, 2002 of 39.0% compares favorably to the effective tax rate of 41.3% for the six months ended June 30, 2001. In the six months ended June 29, 2002, the increased operating income, along with the impact of reduced leverage, increased our pre-tax income. The greater pre-tax income lowered the impact of the permanent differences on the effective tax rate and lead to better utilization of the foreign tax credits.

        Income before Extraordinary Loss.    Income before extraordinary loss for the six months ended June 29, 2002 was $32.0 million, an increase of $14.2 million from $17.8 million for the six months ended June 30, 2001. Income before extraordinary loss for the six months ended June 29, 2002 was 11.8% of net sales, compared to 8.2% of net sales for the six months ended June 30, 2001. The improvement is driven by the increase in operating income, lower effective tax rate and the decrease in interest expense.

        Extraordinary Loss.    We recorded an extraordinary loss of $17.9 million for the six months ended June 29, 2002. The pre-tax loss of $29.3 million is the result of a premium associated with the debt repayments and the write-off of deferred financing costs and original issuance discounts. The related tax benefit was $11.4 million. In the six months ended June 30, 2001, we recorded an extraordinary loss of $1.8 million, net of tax benefit of $1.0 million, as a result of the early repayment of debt.

        Net Income.    The net income for the six months ended June 29, 2002 was $14.1 million, a decrease of $1.9 million compared to a net income of $16.0 million for the six months ended June 30, 2001.

Three Months Ended June 29, 2002 Compared to the Three Months Ended June 30, 2001

        Net Sales.    Net sales for the three months ended June 29, 2002 were $136.5 million, an increase of $19.7 million, or 16.9%, from $116.8 million for the three months ended June 30, 2001. On a pro forma basis, sales increased 15.3% for the three months ended June 29, 2002. Pro forma sales includes net sales of the companies we acquired in 2002 and 2001 as if they occurred at the beginning of fiscal 2001.

        Research Models.    Net sales of research models for the three months ended June 29, 2002 were $56.5 million, an increase of $8.5 million, or 17.7%, from $48.0 million for the three months ended June 30, 2001. Small animal research model sales increased in North America by 16.4% due to an increase in unit volume, a shift to higher priced specialty units including the models from our 2001 acquisition of Genetic Models, Inc. ("GMI") and improved pricing. Excluding positive impact from currency translation of $0.8 million, small animal research model sales in Europe increased 14.3%, driven in part by an increase in unit volume, a shift to higher priced specialty units, and increased equipment sales. Small animal research model sales in Japan increased 9.3% for the three months ended June 29, 2002, excluding the negative impact from currency translation of $0.4 million, due to competitor product quality issues. Sales from our large animal breeding and import conditioning business increased by $2.0 million due mainly to the timing of animal shipments for the three months ended June 29, 2002.

19

---

        Biomedical Products and Services.    Net sales of biomedical products and services for the three months ended June 29, 2002 were $80.0 million, an increase of $11.2 million, or 16.3%, compared to $68.8 million for the three months ended June 30, 2001. Pro forma sales of biomedical products and services increased 15.0% for the three months ended June 29, 2002 compared to the three months ended June 30, 2001. The increase in net sales of biomedical products and services is due to the continued growth in outsourcing in the pharmaceutical industry.

        Cost of Products Sold and Services Provided.    Cost of products sold and services provided for the three months ended June 29, 2002 was $84.1 million, an increase of $11.0 million, or 15.0%, from $73.1 million for the three months ended June 30, 2001. Cost of products sold and services provided for the three months ended June 29, 2002 was 61.6% of the net sales compared to 62.6% for the three months ended June 30, 2001.

        Research Models.    Cost of products sold and services provided for research models for the three months ended June 29, 2002 was $30.4 million, an increase of $3.3 million, or 12.2%, compared to $27.1 million for the three months ended June 30, 2001. Cost of products sold and services provided for the three months ended June 29, 2002 improved to 53.8% of net sales compared to 56.5% of net sales for the three months ended June 30, 2001. Cost of products sold and services provided increased at a lower rate than net sales due to reduced production costs resulting from the closure of a French facility and increased sales which resulted in improved capacity utilization and better efficiencies.

        Biomedical Products and Services.    Cost of products sold and services provided for biomedical products and services for the three months ended June 29, 2002 was $53.7 million, an increase of $7.7 million, or 16.7%, compared to $46.0 million for the three months ended June 30, 2001. Cost of products sold and services provided as a percentage of net sales increased to 67.1% for the three months ended June 29, 2002 from 66.8% for the three months ended June 30, 2001.

        Selling, General and Administrative Expenses.    Selling, general and administrative expenses for the three months ended June 29, 2002 were $21.4 million, an increase of $4.1 million, or 23.7%, from $17.3 million for the three months ended June 30, 2001. Selling, general and administrative expenses for the six months ended June 29, 2002 was 15.7% of net sales compared to 14.8% of net sales for the three months ended June 30, 2001.

        Research Models.    Selling, general and administrative expenses for research models for the three months ended June 29, 2002 were $7.1 million, compared to $7.2 million for the three months ended June 30, 2001. Selling, general and administrative expenses for the three months ended June 29, 2002 was 12.6% of net sales, compared to 15.0% for the three months ended June 30, 2001, principally due to economies of scale.

        Biomedical Products and Services.    Selling, general and administrative expenses for biomedical products and services for the three months ended June 29, 2002 were $9.4 million, an increase of $0.9 million, compared to $8.5 million for the three months ended June 30, 2001. Selling, general and administrative expenses for the three months ended June 29, 2002 was 11.8% of net sales compared to 12.4% of net sales for the three months ended June 30, 2001. Selling, general and administrative expenses increased at a lower rate than net sales due to cost containment during the three months ended June 29, 2002.

        Unallocated Corporate Overhead.    Unallocated corporate overhead, which consists of various corporate expenses, was $4.9 million for the three months ended June 29, 2002, compared to $1.6 million for the three months ended June 30, 2001. The change was caused by decreased pension income and increased administrative expenses including investor relations, security and corporate insurance costs.

20

---

        Amortization of Goodwill and Other Intangibles.    Amortization of goodwill and other intangibles for the three months ended June 29, 2002 was $0.6 million, a decrease of $1.4 million from $2.0 million for the three months ended June 30, 2001. The decrease was due to our adoption of the Financial Accounting Standards Board (FASB) Statement of Financial Accounting Standards No. 142, "Goodwill and Other Intangible Assets" (FAS 142). During the second quarter of 2002, we completed the goodwill impairment test, which identified no potential goodwill impairment as of the beginning of the fiscal year 2002.

        Operating Income.    Operating income for the three months ended June 29, 2002 was $30.4 million, an increase of $5.9 million, or 24.1%, from $24.5 million for the three months ended March 31, 2001. Operating income for the three months ended June 29, 2002 was 22.3% of net sales, compared to 21.0% of net sales for the three months ended June 30, 2001.

        Research Models.    Operating income from sales of research models for the three months ended June 29, 2002 was $19.0 million, an increase of $5.3 million, or 38.7%, from $13.7 million for the three months ended June 30, 2001. Operating income from sales of research models for the three months ended June 29, 2002 was 33.6% of net sales, compared to 28.5% for the three months ended June 30, 2001 due to increased sales and higher gross margins primarily from improved capacity utilization.

        Biomedical Products and Services.    Operating income from sales of biomedical products and services for the three months ended June 29, 2002 was $16.3 million, an increase of $3.8 million, or 30.4%, from $12.5 million for the three months ended June 30, 2001. Operating income from sales of biomedical products and services for the three months ended June 29, 2002 increased to 20.4% of net sales, compared to 18.0% of net sales for the three months ended June 30, 2001, due to the benefit associated with the elimination of goodwill amortization, along with higher operating cost efficiency.

        Interest Expense.    Interest expense for the three months ended June 29, 2002 was $3.0 million, compared to $5.9 million for the three months ended June 30, 2001. The $2.9 million decrease is primarily due to the impact of the tender offer for all of the 13.5% senior subordinated notes completed during the first quarter of 2002, lower interest rate on our 3.5% senior convertible debenture issuance and the payoff of all the term loans during the second quarter of 2002.

        Other Income.    Other income for the three months ended June 29, 2002 was $1.2 million, compared to other expense of $0.1 million for the three months ended June 30, 2001. The increase is due to net foreign currency gains.

        Income Taxes.    The effective tax rate for the three months ended June 29, 2002 of 39.0% compares favorably to the effective tax rate of 40.8% for the three months ended June 30, 2001. In the three months ended June 29, 2002, the increased operating income, along with the impact of reduced leverage, increased our pre-tax income. The greater pre-tax income lowered the impact of the permanent differences on the tax rate and lead to better utilization of the foreign tax credits.

        Income before Extraordinary Loss.    Income before extraordinary loss for the three months ended June 29, 2002 was $17.4 million, an increase of $6.8 million from $10.6 million for the three months ended June 30, 2001. Income before extraordinary loss for the three months ended June 29, 2002 was 12.7% of net sales, compared to 9.1% of net sales for the three months ended June 30, 2001. The improvement is driven by the increase in operating income, lower effective income tax rate and the decrease in interest expense.

        Extraordinary Loss.    We recorded an extraordinary loss of $1.1 million for the three months ended June 29, 2002. The pre-tax loss of $1.8 million is the result of the write-off of deferred financing costs in connection with the debt repayments. The related tax benefit was $0.7 million. In the three months ended June 30, 2001, we recorded an extraordinary loss of $1.6 million, net of tax benefit of $0.8 million, as a result of the early repayment of debt.

21

---

        Net Income.    The net income for the three months ended June 29, 2002 was $16.3 million, an increase of $7.3 million compared to a net income of $9.0 million for the three months ended June 30, 2001.

Liquidity and Capital Resources

        Cash and cash equivalents of the Company totaled $84.7 million at June 29, 2002 compared with $58.3 million at December 29, 2001. Our principal sources of liquidity are cash from operations as well as cash provided by our equity and debt offerings.

        Net cash provided by operating activities for the six months ended June 29, 2002 and June 30, 2001 was $53.6 million and $18.4 million, respectively. The increase in cash provided by operations is primarily a result of our improved performance during the first six months of 2002.

        Net cash used in investing activities during the six months ended June 29, 2002 and June 30, 2001 was $33.8 million and $63.2 million, respectively. The decrease in cash used is a result of more significant business acquisitions in 2001 compared to 2002.

        Net cash provided by financing activities during the six months ended June 29, 2002 and June 30, 2001 was $4.4 million and $41.0 million, respectively. During the first quarter of 2002, we issued $185.0 million par value of senior convertible debentures. We used $79.7 million of the proceeds to repay all of the 13.5% senior subordinated notes. A premium of $23.9 million was paid on the early retirement of the 13.5% senior subordinated notes.

        Minimum future payments of the Company's long term debt at June 29, 2002 are as follows:

        We anticipate that our operating cash flows, together with borrowings under our credit facility, will be sufficient to meet our anticipated future operating expenses, capital expenditures and debt service obligations as they become due.

Item 3.    Quantitative and Qualitative Disclosure About Market Risk

        We are subject to market risks arising from changes in interest rates and foreign currency exchange rates. Our primary interest rate exposure results from changes in LIBOR or the base rate which are used to determine the applicable interest rates under our revolving credit facility. During the second quarter of 2002, we paid off all of our variable rate term loans and have not borrowed against our revolving credit facility, and therefore, are not subject to interest rate risk at this time. Fluctuations in interest rates will not affect the interest payable on the senior convertible debentures, which is fixed.

        We generally do not use financial instruments for trading or other speculative purposes.

        We also have exposure to some foreign currency exchange rate fluctuations for the cash flows received from our foreign affiliates. This risk is mitigated by the fact that their operations are conducted in their respective local currencies. Currently, we do not engage in any foreign currency hedging activities.

Recently Issued Accounting Standards

        In April 2002, the Financial Accounting Standards Board (FASB) issued Statement of Financial Accounting Standards No. 145, "Rescission of FASB Statements No. 4, 44, and 64, Amendment of FASB Statement No. 13, and Technical Corrections" (FAS 145). FAS 145 eliminates the requirement that gains and losses from the extinguishment of debt be aggregated and, if material, classified as an

22

---

extraordinary item, net of the related income tax effect. However, an entity would not be prohibited from classifying such gains and losses as extraordinary items so long as they are both unusual in nature and infrequent in occurrence. This provision of FAS 145 will be effective for the Company as of the beginning of fiscal year 2003. The Company expects to reclassify losses on extinguishment of debt that have been classified as an extraordinary item in prior periods presented.

        In July 2002, the FASB issued Statement of Financial Accounting Standards No. 146, "Accounting for Costs Associated with Exit or Disposal Activities" (FAS 146), which nullifies Emerging Issues Task Force (EITF) Issue No. 94-3, "Liability Recognition for Certain Employee Termination Benefits and Other Costs to Exit an Activity (including Certain Costs Incurred in a Restructuring)". FAS 146 requires a liability for a cost associated with an exit or disposal activity be recognized and measured initially at its fair value in the period in which the liability is incurred. If fair value cannot be reasonably estimated, the liability shall be recognized initially in the period in which fair value can be reasonably estimated. In periods subsequent to the initial measurement, changes to the liability resulting from a revision to either the timing or the amount of estimated cash flows shall be recognized as an adjustment to the liability in the period of the change. The provisions of FAS 146 will be effective for the Company prospectively for exit or disposal activities initiated after December 29, 2002. The Company is in the process of assessing the impact of FAS 146 on its consolidated financial statements.

Factors Affecting Future Results

        This document contains forward looking statements. You can identify these statements by forward looking words such as "may", "will", "expect", "anticipate", "believe", "estimate" and "continue" or similar words. You should read statements that contain these words carefully because they discuss our future expectations, contain projections of our future results of operations or of our financial condition or state other "forward looking" information. We believe that it is important to communicate our future expectations to our investors. However, there may be events in the future that we are not able to accurately predict or control and that may cause our actual results to differ materially from those discussed as a result of various factors, including, but not limited to, our success in selecting and integrating business and technology we acquire, contaminations at our facilities, changes in the pharmaceutical or biotechnology industries, competition and changes in government regulations or general economic or market conditions. These factors should be considered carefully and readers should not place undue reliance on our forward looking statements. We are under no duty to update the forward looking statements after the date of this document or to conform these statements to actual results.

23

---

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
FORM 10Q
For the Quarterly Period Ended June 29, 2002

Item 4.    Submission of Matters to a Vote of Security Holders

        The Company held its Annual Meeting of Shareholders on May 3, 2002. As described in the 2002 Proxy Statement, the following actions were taken:

•

The five nominees for directors were elected.



•

The appointment of PricewaterhouseCoopers LLP as independent auditors for the year 2002 was ratified.

        The votes were as follows:

        For Directors:

        For ratification of independent auditors:

38,464,458 shares voted for; 1,088,094 shares voted against; 2,924 shares abstained from voting.

24

---

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
FORM 10-Q
For the Quarterly Period Ended June 29, 2002

Item 6.    EXHIBITS AND REPORTS ON FORM 8-K

(a)

The following exhibits are included as part of this report on Form 10-Q:

Exhibit Number		Description
2.1		Share Purchase Agreement among the Vendors of Biological Laboratories Europe Limited (as listed in the First Schedule of said agreement), Charles River Europe GmbH and Charles River Laboratories, Inc. dated as of June 7, 2002 (Filed herewith).
10.1		Amendment No. 4 to Amended and Restated Credit Agreement, among Charles River Laboratories International, Inc., Credit Suisse First Boston, as lead arranger, as sole book runner and as syndication agent for the Lenders, and Fleet National Bank, as administrative agent for the Lenders, dated as of June 5, 2002 (Filed herewith).

---

        Where a document is incorporated by reference from a previous filing, the Exhibit number of the document in that previous filing is indicated in parentheses after the description of such document.

(b)

No Reports on Form 8-K were filed during the quarter ended June 29, 2002

25

---

SIGNATURE

        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CHARLES RIVER LABORATORIES
INTERNATIONAL, INC.

August 12, 2002

/S/ JAMES C. FOSTER

---


James C. Foster
Chairman, Chief Executive Officer
and President

/S/ THOMAS F. ACKERMAN

---


Thomas F. Ackerman
Sr. Vice President and Chief Financial Officer

26

---

QuickLinks

RECENT DEVELOPMENTS
Table of Contents
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) (dollars in thousands except for per share data)
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) (dollars in thousands except for per share data)
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (dollars in thousands)
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (dollars in thousands)
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (dollars in thousands)
SIGNATURE